利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.017 秒)

    Recombinant 12-KDA protein useful for the detection of respiratory allergies
    4.
    发明申请
    Recombinant 12-KDA protein useful for the detection of respiratory allergies 审中-公开
    重组12-KDA蛋白可用于检测呼吸道过敏

    公开(公告)号：US20070224608A1

    公开(公告)日：2007-09-27

    申请号：US11585924

    申请日：2006-10-25

    申请人： Naveen Arora ,  Bhanu Pratap Singh ,  Vidhu Sharma

    发明人： Naveen Arora ,  Bhanu Pratap Singh ,  Vidhu Sharma

    IPC分类号： C40B40/08 ,  C40B40/10 ,  C12Q1/68 ,  G01N33/569 ,  C07H21/04 ,  C07K14/37

    CPC分类号： C07K14/37 ,  G01N33/6893 ,  G01N2333/415 ,  G01N2800/12

    摘要： The present invention discloses the detection of an important 12K-Da protein having cross-reactivity amongst different prevalent allergenic grasses and fungi can be useful for detection of respiratory allergies. Conventionally, the whole extracts that are used for diagnosis are unable to specifically detect the causative agents. In addition, they are also responsible for additional non-specific sensitivities in patients to other components present in the extract. If a single cross-reactive protein is available, it can replace large number of extracts used for detection of raised IgE levels in allergy by ELISA, immunoblotting and the likes. Further, number of pricks would be reduced and this would benefit both patient and clinicians. It is further realized that production of such a protein by recombinant methods can lead to its availability in pure form and bulk amounts required for routine diagnosis.

    摘要翻译： 本发明公开了对不同流行的过敏原草和真菌之间具有交叉反应性的重要的12K​​-Da蛋白的检测可用于检测呼吸过敏。 通常，用于诊断的全部提取物不能特异性检测致病因子。 此外，他们还负责在患者中对提取物中存在的其他成分的额外的非特异性敏感性。 如果单个交叉反应蛋白可用，则可以通过ELISA，免疫印迹等替代大量用于检测过敏症中升高的IgE水平的提取物。 此外，将减少窍门的数量，这将有益于患者和临床医师。 进一步认识到，通过重组方法生产这样的蛋白质可以导致其以常规诊断所需的纯形式和体积量的可用性。

    Anthrax toxin fusion proteins, nucleic acid encoding same
    6.
    发明授权
    Anthrax toxin fusion proteins, nucleic acid encoding same 失效
    炭疽毒素融合蛋白，核酸编码相同

    公开(公告)号：US5591631A

    公开(公告)日：1997-01-07

    申请号：US21601

    申请日：1993-02-12

    申请人： Stephen H. Leppla ,  Kurt R. Klimpel ,  Naveen Arora ,  Yogendra Singh ,  Peter J. Nicholls

    发明人： Stephen H. Leppla ,  Kurt R. Klimpel ,  Naveen Arora ,  Yogendra Singh ,  Peter J. Nicholls

    IPC分类号： A61K38/00 ,  A61K47/48 ,  C07K14/16 ,  C07K14/21 ,  C07K14/32 ,  C07K16/00 ,  C07K19/00 ,  C12N15/62 ,  C12N15/31 ,  C12N15/70

    CPC分类号： C07K14/005 ,  A61K47/48276 ,  C07K14/21 ,  C07K14/32 ,  C07K19/00 ,  C12N15/62 ,  A61K38/00 ,  C07K2317/77 ,  C07K2319/00 ,  C07K2319/55 ,  C12N2740/13022

    摘要： The present invention provides a nucleic acid encoding a fusion protein, comprising a nucleotide sequence encoding the protective antigen (PA) binding domain of the native lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein, comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention, vectors comprising the nucleic acids and hosts capable of expressing the protein encoded by the nucleic acids are also provided. A composition comprising the PA binding domain of the native LF protein chemically attached to a non-LF activity inducing moiety is further provided. A method for delivering an activity to a cell is provided. The steps of the method include administering to the cell a protein comprising the translocation domain and the LF binding domain of the native PA protein and a ligand domain, and administering to the cell a product comprising the PA binding domain of the native LF protein and a non-LF activity inducing moiety, whereby the product administered is internalized into the cell and performs the activity within the cell.

    摘要翻译： 本发明提供编码融合蛋白的核酸，其包含编码天然致死因子（LF）蛋白的保护性抗原（PA）结合结构域的核苷酸序列和编码第二蛋白质的活性诱导结构域的核苷酸序列。 还提供了编码融合蛋白的核酸，其包含编码天然PA蛋白的易位结构域和LF结合结构域的核苷酸序列和编码特异性结合细胞靶标的配体结构域的核苷酸序列。 还提供了由本发明的核酸编码的蛋白质，包含能够表达由核酸编码的蛋白质的核酸和宿主的载体。 进一步提供包含与非LF活性诱导部分化学连接的天然LF蛋白的PA结合结构域的组合物。 提供了将活动递送到小区的方法。 该方法的步骤包括向细胞施用包含天然PA蛋白的易位结构域和LF结合结构域的蛋白质和配体结构域，并向细胞施用包含天然LF蛋白质的PA结合结构域的产物和 非LF活性诱导部分，由此所施用的产物内化到细胞中并在细胞内进行活性。

    RECOMBINANT 12-KDA PROTEIN USEFUL FOR THE DETECTION OF RESPIRATORY ALLERGIES
    7.
    发明申请
    RECOMBINANT 12-KDA PROTEIN USEFUL FOR THE DETECTION OF RESPIRATORY ALLERGIES 审中-公开
    用于检测呼吸道过敏症的重组12-KDA蛋白质

    公开(公告)号：US20110076702A1

    公开(公告)日：2011-03-31

    申请号：US12885385

    申请日：2010-09-17

    申请人： Naveen ARORA ,  Bhanu Pratap Singh ,  Vidhu Sharma

    发明人： Naveen ARORA ,  Bhanu Pratap Singh ,  Vidhu Sharma

    IPC分类号： G01N33/53

    CPC分类号： C07K14/37 ,  G01N33/6893 ,  G01N2333/415 ,  G01N2800/12

    摘要： The present invention discloses the detection of an important 12K-Da protein having cross-reactivity amongst different prevalent allergenic grasses and fungi can be useful for detection of respiratory allergies. Conventionally, the whole extracts that are used for diagnosis are unable to specifically detect the causative agents. In addition, they are also responsible for additional non-specific sensitivities in patients to other components present in the extract. If a single cross-reactive protein is available, it can replace large number of extracts used for detection of raised IgE levels in allergy by ELISA, immunoblotting and the likes. Further, number of pricks would be reduced and this would benefit both patient and clinicians. It is further realized that production of such a protein by recombinant methods can lead to its availability in pure form and bulk amounts required for routine diagnosis.

    摘要翻译： 本发明公开了对不同流行的过敏原草和真菌之间具有交叉反应性的重要的12K​​-Da蛋白的检测可用于检测呼吸过敏。 通常，用于诊断的全部提取物不能特异性检测致病因子。 此外，他们还负责在患者中对提取物中存在的其他成分的额外的非特异性敏感性。 如果单个交叉反应蛋白可用，则可以通过ELISA，免疫印迹等替代大量用于检测过敏症中升高的IgE水平的提取物。 此外，将减少窍门的数量，这将有益于患者和临床医师。 进一步认识到，通过重组方法生产这样的蛋白质可以导致其以常规诊断所需的纯形式和体积量的可用性。

    Anthrax toxin fusion proteins and related methods
    8.
    发明授权
    Anthrax toxin fusion proteins and related methods 失效
    炭疽毒素融合蛋白及相关方法

    公开(公告)号：US5677274A

    公开(公告)日：1997-10-14

    申请号：US82849

    申请日：1993-06-25

    申请人： Stephen H. Leppla ,  Kurt R. Klimpel ,  Naveen Arora ,  Yogendra Singh ,  Peter J. Nichols

    发明人： Stephen H. Leppla ,  Kurt R. Klimpel ,  Naveen Arora ,  Yogendra Singh ,  Peter J. Nichols

    IPC分类号： A61K38/00 ,  A61K47/48 ,  C07K14/16 ,  C07K14/21 ,  C07K14/32 ,  C07K16/00 ,  C07K19/00 ,  C12N15/62 ,  A61K39/00

    CPC分类号： C07K14/005 ,  A61K47/48276 ,  C07K14/21 ,  C07K14/32 ,  C07K16/00 ,  C07K19/00 ,  C12N15/62 ,  A61K38/00 ,  C07K2317/77 ,  C07K2319/00 ,  C07K2319/55 ,  C12N2740/13022 ,  C12N2740/16222

    摘要： The present invention provides a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native anthrax PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention, vectors comprising the nucleic acids and hosts capable of expressing the protein encoded by the nucleic acids are also provided. A composition comprising the PA binding domain of the native LF protein chemically attached to a non-LF activity inducing moiety is further provided. A method for delivering an activity to a cell is provided. The steps of the method include a) administering to the cell a protein comprising the translocation domain and the LF binding domain of the native PA protein and a ligand domain, and b) administering to the cell a product comprising the PA binding domain of the native LF protein and a non-LF activity inducing moiety, whereby the product administered in step b) is internalized into the cell and performs the activity within the cell. The invention also provides proteins including an anthrax protective antigen which has been mutated to replace the trypsin cleavage site with residues recognized specifically by the HIV-1 protease.

    摘要翻译： 本发明提供编码融合蛋白的核酸，其包含编码天然炭疽致死因子（LF）蛋白质的炭疽保护性抗原（PA）结合结构域的核苷酸序列和编码第二蛋白质的活性诱导结构域的核苷酸序列。 还提供了编码融合蛋白的核酸，其包含编码天然炭疽PA蛋白的易位结构域和LF结合结构域的核苷酸序列和编码特异性结合细胞靶标的配体结构域的核苷酸序列。 还提供了由本发明的核酸编码的蛋白质，包含能够表达由核酸编码的蛋白质的核酸和宿主的载体。 进一步提供包含与非LF活性诱导部分化学连接的天然LF蛋白的PA结合结构域的组合物。 提供了将活动递送到小区的方法。 该方法的步骤包括a）向细胞施用包含天然PA蛋白和配体结构域的易位结构域和LF结合结构域的蛋白质，和b）向细胞施用包含天然的PA结合结构域的产物 LF蛋白和非LF活性诱导部分，由此将步骤b）中给药的产物内化到细胞中并在细胞内进行活性。 本发明还提供蛋白质，其包括已被突变以用胰蛋白酶切割位点代替由HIV-1蛋白酶特异识别的残基的炭疽保护性抗原。

    Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
    9.
    发明授权
    Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein 失效
    将抗原用炭疽毒素融合蛋白靶向MHC I类加工途径

    公开(公告)号：US06592872B1

    公开(公告)日：2003-07-15

    申请号：US08937276

    申请日：1997-09-15

    申请人： Kurt Klimpel ,  Theresa J. Goletz ,  Naveen Arora ,  Stephen H. Leppla ,  Jay A. Berzofsky

    发明人： Kurt Klimpel ,  Theresa J. Goletz ,  Naveen Arora ,  Stephen H. Leppla ,  Jay A. Berzofsky

    IPC分类号： A61K3907

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K14/32 ,  C07K2319/00 ,  C12N2740/16122 ,  Y02A50/412 ,  Y02A50/423 ,  Y10S514/885 ,  Y10S530/806 ,  Y10S530/825

    摘要： The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine comprising an anthrax protective antigen and a full length protein antigen bound to a nontoxic anthrax protective antigen binding protein comprising at least about the first 250 amino acid residues of the lethal factor of Bacillus anthracis and less than all of the amino acid residues of the lethal factor. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.

    摘要翻译： 本发明提供了用于在哺乳动物中诱导特异性抗原的免疫应答的疫苗，其中疫苗包含单位剂量的二元细胞毒性T淋巴细胞疫苗，其包含炭疽保护性抗原和与无毒性炭疽保护性结合的全长蛋白质抗原 抗原结合蛋白，其包含至少约大约碳芽孢杆菌致死因子的250个氨基酸残基并且小于致死因子的全部氨基酸残基。 本发明还提供了使用该疫苗免疫哺乳动物抗原的方法，以及通过MHC I类加工途径诱导抗原呈递哺乳动物细胞呈递特异性抗原的方法。